Loading...

PE/Cyanine7 anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_PECy7_030206
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) PE/Cyanine7 (filled histogram) or rat IgG2a, κ PE/Cyanine7 isotype control (open histogram).
  • RM4-5_PECy7_030206
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) PE/Cyanine7 (filled histogram) or rat IgG2a, κ PE/Cyanine7 isotype control (open histogram).
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100527 25 µg 71€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100528 100 µg 159€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  2. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  3. Lynn MA, et al. 2022. STAR Protoc. 3:101914. PubMed
  4. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  5. Zhao L, et al. 2022. Oncogene. 41:4200. PubMed
  6. Balmert SC, et al. 2022. iScience. 25:105045. PubMed
  7. Harapas CR, et al. 2022. Sci Immunol. 7:eabi4611. PubMed
  8. Brunner SM, et al. 2023. Int J Mol Sci. 24:. PubMed
  9. Pandit M, et al. 2023. Nat Commun. 14:2593. PubMed
  10. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  11. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  12. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  13. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  14. Du C, et al. 2016. Nat Commun. 7: 11120. PubMed
  15. Nocera D, et al. 2016. J Immunol. 196: 2860 - 2869. PubMed
  16. Gravano D, et al. 2010. PLoS One. 5:e13528. PubMed
  17. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  18. Hastings AK, et al. 2019. iScience. 13:339. PubMed
  19. Wang D, et al. 2018. Immunity. 48:659. PubMed
  20. Gengenbacher M, et al. 2016. MBio. 7: 00679-16. PubMed
  21. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  22. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  23. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  24. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  25. Guo Q, et al. 2021. Front Cardiovasc Med. 8:633212. PubMed
  26. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
  27. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  28. Choi JY, et al. 2020. Proc Natl Acad Sci U S A. 117:6042. PubMed
  29. Schaller M, et al. 2015. J Leukoc Biol. 98: 601 - 613. PubMed
  30. Bhattacharjee S, et al. 2019. Cell Rep. 28:231. PubMed
  31. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  32. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  33. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  34. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  35. Kedage V, et al. 2022. MAbs. 14:2040083. PubMed
  36. Blankenhaus B, et al. 2014. PLoS Pathog. 10:1003913. PubMed
  37. Miyazaki M et al. 2017. Immunity. 46(5):818-834 . PubMed
  38. Ly A, et al. 2020. Cell Reports. 29(8):2257-2269.e6.. PubMed
  39. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  40. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  41. Daniel CJ, et al. 2022. Mol Cancer Res. 20:1151. PubMed
  42. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  43. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  44. JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed
  45. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  46. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  47. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  48. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
  49. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  50. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  51. Macdougall CE et al. 2018. Cell metabolism. 27(3):588-601 . PubMed
  52. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
  53. Carty S, et al. 2014. PLoS One. 9:106659. PubMed
  54. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  55. Studniberg SI, et al. 2022. Mol Syst Biol. 18:e10824. PubMed
  56. Riding AM, et al. 2022. iScience. 25:104660. PubMed
  57. Ballet R, et al. 2014. PLoS Pathog. 10:1004550. PubMed
  58. Xu X, et al. 2018. J Dermatol Sci. 91:134. PubMed
  59. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  60. Mandal RK, et al. 2021. Cell Reports. 35(6):109094. PubMed
  61. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  62. Frohner IE, et al. 2020. Cell Rep. 30:3171. PubMed
  63. Macagno M, et al. 2014. J Immunol. 192:5434. PubMed
  64. Di Lorenzo A, et al. 2022. Oncoimmunology. 11:2086752. PubMed
  65. Laubreton D, et al. 2020. Viruses. 12:00. PubMed
  66. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  67. Kim D, et al. 2020. Immunity. 53(3):581-596.e5. PubMed
  68. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  69. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  70. Guan D, et al. 2021. Cell Death Dis. 12:431. PubMed
  71. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed
  72. Ryg-Cornejo V, et al. 2016. Cell Rep. 14:68-81. PubMed
  73. Chong WP, et al. 2020. Immunity. 53(2):384-397.e5.. PubMed
  74. Platteel ACM, et al. 2018. Front Immunol. 1.544444444. PubMed
  75. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  76. Hassan H, et al. 2011. Proc Natl Acad Sci U S A. 108:18330. PubMed
  77. Lau A, et al. 2022. Sci Adv. 8:eabm0142. PubMed
  78. Dietschmann A, et al. 2020. Eur J Immunol. 50:1044. PubMed
  79. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  80. C Khouili S, et al. 2020. Cell Rep. 33:108468. PubMed
  81. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  82. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  83. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
RRID
AB_312729 (BioLegend Cat. No. 100527)
AB_312729 (BioLegend Cat. No. 100528)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 3    Revision Date: 01.29.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account